Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1\/2\/MTOR Alterations From Others.<\/p>\n
Authors: Huili Li, Pedram Argani, Eitan Halper-Stromberg, Tamara L Lotan, Maria J Merino, Victor E Reuter, Andres Matoso
\nThe American Journal of Surgical Pathology. 47(11):1267-1273, November 2023.
\nFREE LINK (expires 1\/22\/24)
\n<a
\nhttps:\/\/journals.lww.com\/ajsp\/fulltext\/2023\/11000\/positive_gpnmb_immunostaining_differentiates_renal.8.aspx<\/p>\n
Précis<\/em><\/p>\n The authors conducted a study evaluating immunoexpression of a (glycoprotein nonmetastatic B) (GPNMB) antibody in 7 cases of molecularly confirmed ELOC-mutated renal cell carcinoma, 6 cases of renal cell carcinoma with fibromyomatous stroma (RCCFMS) with TSC1\/2\/mTOR alterations, 7 cases of clear cell papillary renal cell tumor (CCPRCR), and 8 cases of clear cell renal cell carcinoma (ccRCC) and found that GPNMB was positive in tumors with TSC1\/2\/mTOR alterations, while negative in all others with the exception of focal weak staining in two cases of clear cell renal cell carcinoma, suggesting that the immunoexpression of GPNMB can distinguish RCCFMS with TSC1\/2\/mTOR alterations from other neoplasms with overlapping morphology.<\/p>\n Comment<\/em><\/p>\n The 5th edition of the WHO classification of urinary and male genital tumours<\/i>(2022) now includes the category of molecularly defined renal carcinomas. However, the molecular tests essential to the diagnosis of tumors like ELOC-mutated renal cell carcinoma are not readily widely available for use in diagnostic practice for most pathologists, of most pathologists or it might be expensive. Therefore, there is a need for the development of additional inexpensive diagnostic ancillary tests with quick turnaround time. The use of GPNMB immunohistochemical stain described in this timely article might provide diagnostic utility in the diagnosis of RCCFMS with TSC1\/2\/mTOR alterations. However, the study is limited by a low number of cases and GPNMB antibody is not yet widely available in the most diagnostic laboratories. Given the potential utility of GPNMB expression in other renal tumors, such as MiT family translocation RCCs, eosinophilic solid and cystic RCC, and low-grade oncocytic tumors, the awareness of the findings of this study can provide more rationale for introducing GPNMB antibody in the test menu of the immunohistochemistry laboratories. The author responds (Dr. Andres Matoso):<\/em><\/p>\n We agree with the summary.<\/p>\n<\/body><\/html>\n","protected":false},"excerpt":{"rendered":" Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1\/2\/MTOR Alterations From Others. Authors: Huili Li, Pedram Argani, Eitan Halper-Stromberg, Tamara L Lotan, Maria J Merino, Victor E Reuter, Andres Matoso The American Journal of Surgical Pathology. 47(11):1267-1273, November 2023. FREE LINK (expires 1\/22\/24) <a https:\/\/journals.lww.com\/ajsp\/fulltext\/2023\/11000\/positive_gpnmb_immunostaining_differentiates_renal.8.aspx Précis The authors conducted a study … Continue reading FOURTH QUARTER OF 2023<\/span>
\nReviewer: Oleksandr Kravtsov, MD<\/p>\n